GlassScriptPhysician profile
Kook I Chang
NPI 1356442354
$8,463.12
in general payments reported to CMS, 2019-2025
30 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,119 · 2020: $659 · 2021: $1,421 · 2022: $1,124 · 2023: $1,190 · 2024: $787 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,140.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,258.16 | 2019-2024 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $937.55 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $880.10 | 2019-2025 | Linzess, Creon, Viberzi |
| Amgen INC. | $711.66 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $468.41 | 2019-2025 | Jardiance, Kisunla, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $420.64 | 2023-2025 | |
| Kvk-Tech, INC. | $414.99 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.13 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $310.76 | 2022-2025 | Camzyos |
| Nestle Healthcare Nutrition INC. | $291.71 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $286.68 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $248.88 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $215.41 | 2019-2023 | Trintellix |
| Ironwood Pharmaceuticals, INC | $197.81 | 2019-2025 | Linzess |
| Sunovion Pharmaceuticals INC. | $184.62 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $177.32 | 2019-2021 | |
| Aimmune Therapeutics, INC. | $147.99 | 2025 | Zenpep |
| Amarin Pharma, INC. | $136.65 | 2019-2022 | |
| Abbott Laboratories | $128.09 | 2019 | |
| Gilead Sciences, INC. | $127.32 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $115.83 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.81 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $90.10 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $79.06 | 2021 | |
| Astellas Pharma US INC | $40.32 | 2019-2020 | |
| Allergan, INC. | $38.26 | 2019 | |
| Radius Health, INC. | $34.96 | 2025 | |
| Corium, LLC | $33.79 | 2023 | Adlarity |
| Scilex Pharmaceuticals INC. | $19.62 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kook Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.